KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Debt (2022 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Total Debt for 4 consecutive years, with $131.2 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 1.55% to $131.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.2 million through Dec 2025, down 1.55% year-over-year, with the annual reading at $131.2 million for FY2025, 1.55% down from the prior year.
  • Total Debt hit $131.2 million in Q4 2025 for Adaptive Biotechnologies, roughly flat from $131.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $133.6 million in Q2 2025 to a low of $125.4 million in Q4 2022.
  • Historically, Total Debt has averaged $131.4 million across 4 years, with a median of $131.8 million in 2025.
  • Biggest five-year swings in Total Debt: rose 4.23% in 2023 and later decreased 1.55% in 2025.
  • Year by year, Total Debt stood at $125.4 million in 2022, then increased by 4.23% to $130.7 million in 2023, then grew by 2.0% to $133.3 million in 2024, then dropped by 1.55% to $131.2 million in 2025.
  • Business Quant data shows Total Debt for ADPT at $131.2 million in Q4 2025, $131.8 million in Q3 2025, and $133.6 million in Q2 2025.